Compare GLOB & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLOB | ODTX |
|---|---|---|
| Founded | 2003 | 2021 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2015 | 2025 |
| Metric | GLOB | ODTX |
|---|---|---|
| Price | $41.60 | $16.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 8 |
| Target Price | ★ $52.10 | $34.67 |
| AVG Volume (30 Days) | ★ 1.0M | 291.0K |
| Earning Date | 11-19-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.28 | N/A |
| P/E Ratio | $22.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.56 | $15.10 |
| 52 Week High | $72.10 | $29.05 |
| Indicator | GLOB | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 36.09 |
| Support Level | $34.29 | $15.73 |
| Resistance Level | $44.64 | $19.60 |
| Average True Range (ATR) | 2.16 | 1.69 |
| MACD | -1.09 | -0.19 |
| Stochastic Oscillator | 12.42 | 6.10 |
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.